NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Mechanism of Action
metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. The first step in the detoxification process is the binding of mesna to 4‑hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide. Mesna also binds to the double bonds of acrolein and to other urotoxic…
Indications (1)
Clinical Trials (2)
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
Started Sep 2014
70 enrolled
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Started Aug 2004
160 enrolled
AnemiaDrug/Agent Toxicity by Tissue/OrganLung Cancer+1 more